Allergan PLC. (AGN-N) Stock Predictions - Stockchase
WATCH LIST
42
Allergan PLC. (AGN-N)

ON STOCKCHASE SINCE May 2003

Formerly Watson Pharmaceuticals Inc

Formerly Actavis (June 2015)

Consumer Products

Allergan PLC.

AGN-N

8 watching          
Join the Discussion

Allergan PLC. (AGN-N) SAVE Apr, 19, 2019, 9:12 am

140.31 0.28 (0.2%)

What the experts are saying about AGN-N



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Allergan PLC.(AGN-N) 

January 17, 2019

(A Top Pick Dec 15/18, Down 8%) He sold in the $1.90 range. There is talk of them spinning out their cosmetic division but it has not happened yet. He could get back into it. He was unfortunate trading this.
Consumer Products
0 0 0 0 0
0 comments
(A Top Pick Dec 15/18, Down 8%) He sold in the $1.90 range. There is talk of them spinning out their cosmetic division but it has not happened yet. He could get back into it. He was unfortunate trading this.
Consumer Products
0 0 0 0 0
0 comments
Michael Simpson

Senior Vic, Sentry Investments...

Price Price
$156.560
Owned Owned
No

PAST TOP PICK
Allergan PLC.(AGN-N) 

July 5, 2018

(A Top Pick September 14/17-  Down 22%.) This was a high-risk position. They sold a drug to a native band and then they leased the rights back to circumvent potential generic competition. Something cheeky and probably that is why the stock sold off. Their strength is still in Botox and aesthetics. He doesn’t see that changing or being threat. He still likes it. Management is under the gun. 

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick September 14/17-  Down 22%.) This was a high-risk position. They sold a drug to a native band and then they leased the rights back to circumvent potential generic competition. Something cheeky and probably that is why the stock sold off. Their strength is still in Botox and aesthetics. He doesn’t see that changing or being threat. He still likes it. Management is under the gun. 

Consumer Products
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$172.200
Owned Owned
Yes

DON'T BUY
Allergan PLC.(AGN-N) 

May 24, 2018

Form a valuation standpoint, trading at 10 times forward earnings with high single digit growth rate. But the stock keeps falling down. He would be very careful with this. Could be a value trap. 

Consumer Products
0 0 0 0 0
0 comments

Form a valuation standpoint, trading at 10 times forward earnings with high single digit growth rate. But the stock keeps falling down. He would be very careful with this. Could be a value trap. 

Consumer Products
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$154.000
Owned Owned
No

TOP PICK
Allergan PLC.(AGN-N) 

December 14, 2017

They are the maker of Botox.  They have a drug for dry eye syndrome that will come off patent but his analysis of the case for losing all revenue from the drug has them still doing well.  They have a good drug pipeline.  (Analysts’ target: $225.00).

Consumer Products
0 0 0 0 0
0 comments

They are the maker of Botox.  They have a drug for dry eye syndrome that will come off patent but his analysis of the case for losing all revenue from the drug has them still doing well.  They have a good drug pipeline.  (Analysts’ target: $225.00).

Consumer Products
0 0 0 0 0
0 comments
Michael Simpson

Senior Vic, Sentry Investments...

Price Price
$170.940
Owned Owned
Yes

SELL
Allergan PLC.(AGN-N) 

December 7, 2017

Their number 1 product is Botox and their number 2 product is eye drops, and there is some competition coming from generics for their eyedrops drug. Thinks that is what has been hurting the stock recently. When the technicals are working against you where a stock has fallen below the 200-day moving average, and the price is below both the 50 day and 100 day, technically you want to step away.

Consumer Products
0 0 0 0 0
0 comments

Their number 1 product is Botox and their number 2 product is eye drops, and there is some competition coming from generics for their eyedrops drug. Thinks that is what has been hurting the stock recently. When the technicals are working against you where a stock has fallen below the 200-day moving average, and the price is below both the 50 day and 100 day, technically you want to step away.

Consumer Products
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$164.870
Owned Owned
No

SELL
Allergan PLC.(AGN-N) 

October 18, 2017

(Market Call Minute.) A broken stock and he would Sell it and move on.

Consumer Products
0 0 0 0 0
0 comments

(Market Call Minute.) A broken stock and he would Sell it and move on.

Consumer Products
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$187.150
Owned Owned
Unknown

DON'T BUY
Allergan PLC.(AGN-N) 

September 21, 2017

We are in a structural bull market for equities.  We are skating through the two toughest months of the year without much volatility.  Don’t buy a company that has been put into the penalty box.  Stocks that have broken down have an army of people who just want to get their money back.

Consumer Products
0 0 0 0 0
0 comments

We are in a structural bull market for equities.  We are skating through the two toughest months of the year without much volatility.  Don’t buy a company that has been put into the penalty box.  Stocks that have broken down have an army of people who just want to get their money back.

Consumer Products
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$202.660
Owned Owned
Unknown

TOP PICK
Allergan PLC.(AGN-N) 

September 14, 2017

They are known for Botox.  Aesthetics is a big part of their business as well as a great urology business and Gastro Intestinal business.  They sold their urology business and reinvested their cash into R&D.  It is very inexpensive.  (Analysts’ target: $271.50).

Consumer Products
0 0 0 0 0
0 comments

They are known for Botox.  Aesthetics is a big part of their business as well as a great urology business and Gastro Intestinal business.  They sold their urology business and reinvested their cash into R&D.  It is very inexpensive.  (Analysts’ target: $271.50).

Consumer Products
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$223.700
Owned Owned
Yes

COMMENT
Allergan PLC.(AGN-N) 

May 10, 2017

This has things like Botox, etc., but also have some things on the pharmaceutical side. He felt that they had a great quarter. Made 10 acquisitions in the past year with the proceeds of the generics they sold to Teva. Trading around 13X forward earnings, so not terribly expensive. He likes this one.

Consumer Products
0 0 0 0 0
0 comments

This has things like Botox, etc., but also have some things on the pharmaceutical side. He felt that they had a great quarter. Made 10 acquisitions in the past year with the proceeds of the generics they sold to Teva. Trading around 13X forward earnings, so not terribly expensive. He likes this one.

Consumer Products
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$229.720
Owned Owned
Yes

COMMENT
Allergan PLC.(AGN-N) 

March 13, 2017

He likes the pharmaceuticals. They are under a bit of pressure from legislation on repricing, but thinks most of that is priced in. He would say “yes” for this one.

Consumer Products
0 0 0 0 0
0 comments

He likes the pharmaceuticals. They are under a bit of pressure from legislation on repricing, but thinks most of that is priced in. He would say “yes” for this one.

Consumer Products
0 0 0 0 0
0 comments
Matt Kacur

President, FSA Financial Scienc...

Price Price
$240.650
Owned Owned
Unknown

PAST TOP PICK
Allergan PLC.(AGN-N) 

February 9, 2017

(Top Pick Nov 29/16, Up 28.87%) He still likes it despite the return.  They are very diligent at returning to shareholders.  They have been making strategic acquisitions and their pipeline is full.  He continues to like it.

Consumer Products
0 0 0 0 0
0 comments

(Top Pick Nov 29/16, Up 28.87%) He still likes it despite the return.  They are very diligent at returning to shareholders.  They have been making strategic acquisitions and their pipeline is full.  He continues to like it.

Consumer Products
0 0 0 0 0
0 comments
John Petrides

Managing D, Point View Wealth Ma...

Price Price
$245.680
Owned Owned
Yes

PAST TOP PICK
Allergan PLC.(AGN-N) 

January 10, 2017

(A Top Pick Aug 17/16. Down 13.44%.) A terrific company, and shows up as the highest quality company in its group. Unfortunately, they got painted by the specialty pharmaceutical brush. It is getting a bit of a reprieve right now. He still likes this. It has one of the best growth profiles of any of the specialty pharmaceutical companies. The majority of its businesses are not subject to the same type of price controls that could come under government scrutiny.

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick Aug 17/16. Down 13.44%.) A terrific company, and shows up as the highest quality company in its group. Unfortunately, they got painted by the specialty pharmaceutical brush. It is getting a bit of a reprieve right now. He still likes this. It has one of the best growth profiles of any of the specialty pharmaceutical companies. The majority of its businesses are not subject to the same type of price controls that could come under government scrutiny.

Consumer Products
0 0 0 0 0
0 comments
Bruce Tatters

Founding P, Triumph Asset Manage...

Price Price
$221.250
Owned Owned
Yes

COMMENT
Allergan PLC.(AGN-N) 

November 30, 2016

United Therapeutic (UTHR-Q) or Allergan (AGN-N)? This is a tough one because they are 2 very different companies. Of the 2, this is a much larger company and more broadly-based.

Consumer Products
0 0 0 0 0
0 comments

United Therapeutic (UTHR-Q) or Allergan (AGN-N)? This is a tough one because they are 2 very different companies. Of the 2, this is a much larger company and more broadly-based.

Consumer Products
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$194.300
Owned Owned
Unknown

TOP PICK
Allergan PLC.(AGN-N) 

November 29, 2016

The healthcare sector has been the worst sector of the S&P 500 year-to-date, and yet the long-term fundamentals are still very strong. You have a growing global population and an aging population. That means the healthcare system, from a utilization standpoint, is going to continue to be under a lot of pressure regardless of Obama care. The valuation on the healthcare sector in general has not been this low since 2009 and back in 1994 for the past 25 years. They recently sold their generic business to Teva (TEVA-N) and got $40 billion. They are using the cash to buy back debt and to buy back stock. This owns Botox, one of the largest consumer drugs in the world. They are using the cash they got, to make small acquisitions to bolster their drug pipeline. Dividend yield of 1.44%. (Analysts’ price target is $266.11.)

Consumer Products
0 0 0 0 0
0 comments

The healthcare sector has been the worst sector of the S&P 500 year-to-date, and yet the long-term fundamentals are still very strong. You have a growing global population and an aging population. That means the healthcare system, from a utilization standpoint, is going to continue to be under a lot of pressure regardless of Obama care. The valuation on the healthcare sector in general has not been this low since 2009 and back in 1994 for the past 25 years. They recently sold their generic business to Teva (TEVA-N) and got $40 billion. They are using the cash to buy back debt and to buy back stock. This owns Botox, one of the largest consumer drugs in the world. They are using the cash they got, to make small acquisitions to bolster their drug pipeline. Dividend yield of 1.44%. (Analysts’ price target is $266.11.)

Consumer Products
0 0 0 0 0
0 comments
John Petrides

Managing D, Point View Wealth Ma...

Price Price
$192.640
Owned Owned
Yes

PAST TOP PICK
Allergan PLC.(AGN-N) 

November 21, 2016

(Top Pick Dec 10/15, Down 37.63%) Everyone got blindsided when the US government stopped the deal with PFE-N.  But look at the M&A that has started since the election.  He scaled the position back a bit

Consumer Products
0 0 0 0 0
0 comments

(Top Pick Dec 10/15, Down 37.63%) Everyone got blindsided when the US government stopped the deal with PFE-N.  But look at the M&A that has started since the election.  He scaled the position back a bit

Consumer Products
0 0 0 0 0
0 comments
Bruce Tatters

Founding P, Triumph Asset Manage...

Price Price
$191.140
Owned Owned
Yes

Showing 1 to 15 of 42 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days